Table of Contents:

1 Report Prologue
1.1 Increasing awareness of lancet and pen needles:
1.2 Production of lancet and pen needles:
1.3 FDA Regulation for Lancet:
2 Market Introduction
2.1 Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of diabetes
4.2.2 Growing incidence number of contagious and non-contagious diseases
4.2.3 Increasing inclination towards home healthcare
4.2.4 Improving Medical Device Regulation
4.3 Restraints
4.3.1 Risk associated with blood transfusion
4.3.2 Growing adoption of oral drug delivery systems, reuse of pen needles and infusion sets
4.4 Opportunities
4.5 Mega Trends:
4.6 Macroeconomic Indicators
?
5 Market Factor Analysis
5.1 Porter's Five forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Global Lancet And Pen Needles Market, By Type
6.1 Lancet
6.1.1 Regular Lancet
6.1.2 Safety Lancet
6.1.2.1 Push Button Safety Lancet
6.1.2.2 Pressure Activated Safety Lancet
6.1.2.3 Side Button Safety Lancet
6.2 Pen Needles
6.2.1 Standard Needles
6.2.2 Safety Needles
7 Global Lancet And Pen Needles Market, By Application
7.1 Insulin
7.2 Capillary Blood Sampling
7.3 Hormones
7.4 Glucose Like Peptide (GLP)
7.5 Skin Testing
8 Global Lancet And Pen Needles Market, By End User
8.1 Hospitals & Clinics
8.2 Diagnostic Centers & Medical Institutions
8.3 Home Care & Home Diagnostics
8.4 Research & Academic Laboratories
9 Global Lancet and Pen Needles Market, By Region
9.1 Introduction
9.2 Europe
9.2.1 Western Europe
9.2.1.1 Germany
9.2.1.2 France
9.2.1.3 U.K
9.2.1.4 Italy
9.2.1.5 SPAIN
9.2.1.6 Rest of Western Europe
9.2.2 Eastern Europe
9.3 Americas
9.3.1 North America
9.3.1.1 U.S.
9.3.1.2 Canada
9.3.2 South America
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 South Korea
9.4.5 Australia
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 UAE
9.5.2 Saudi Arabia
9.5.3 Kuwait
9.5.4 Qatar
9.5.5 Africa
10 Competitive Landscape
10.1 Introduction
10.1 Company Share Analysis
11 Company Profile
11.1 B. Braun Melsungen AG
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Terumo Corporation
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Becton Dickinson
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 Sanofi
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 F. Hoffmann-La Roche AG
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Bayer AG
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Novo Nordisk A S
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
11.8 Eli Lilly and Company
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Owen Mumford Ltd
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.1 Medtronic
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 Ypsomed Holding AG
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Strategy
11.11.5 Key Developments
11.12 Sarstedt AG & Co
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Strategy
11.12.5 Key Developments
11.13 Greiner Bio One
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Products
11.13.4 Strategy
11.13.5 Key Developments
11.14 Abbott Laboratories
11.14.1 Company Overview
11.14.2 Financials
11.14.3 Products
11.14.4 Strategy
11.14.5 Key Developments
11.15 HTL-STREFA S.A.
11.15.1 Company Overview
11.15.2 Financials
11.15.3 Products
11.15.4 Strategy
11.15.5 Key Developments
11.16 Improve Medical
11.16.1 Company Overview
11.16.2 Financials
11.16.3 Products
11.16.4 Strategy
11.16.5 Key Developments
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of lancet and pen needles Industry
13 Appendix
13.1 Discussion Blue Print